NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.
Stock data | 2024 | Change |
---|---|---|
Price | $0.763 | N/A |
Market Cap | $16.70M | N/A |
Shares Outstanding | 21.89M | N/A |
Employees | 0 | N/A |